ESGO 2021 | Endometrial Cancer Health Outcomes: pembrolizumab for patients with MSI-high endometrial cancer

Vimalanand Prabhu, PhD, Merck, Lansdale, PA, discusses the retrospective, multicenter chart review study, Endometrial Cancer Health Outcomes (ECHO). ECHO looked at real-world outcomes in adult women with MSI-high or dMMR advanced/inoperable endometrial cancer, who had progressed after prior systemic therapy. The majority of these patients received second-line immunotherapy with pembrolizumab and achieved a good prognosis, leading to this regimen becoming standard of care. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.